We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Xolair for Young Asthmatics Rejected by Committee
Xolair for Young Asthmatics Rejected by Committee
November 20, 2009
An FDA advisory committee voted 10–4 not to recommend that the FDA expand Genentech and Novartis’ asthma drug Xolair’s indication to
treat children age 6 to 11 with moderate-to-severe persistent asthma.